Secondary prophylaxis in an adult patient with severe haemophilia A Factor VIII consumption and effectiveness

被引:2
|
作者
Schlenkrich, S. [1 ]
Schubert, C. [1 ]
机构
[1] HELIOS Clin Ctr Erfurt, Erfurt, Germany
来源
HAMOSTASEOLOGIE | 2013年 / 33卷 / 03期
关键词
Haemophilia; secondary prophylaxis; adult; bleeding rate; factor VIII consumption;
D O I
10.5482/HAMO-12-07-0013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary prophylaxis has been proven as the gold standard for preserving joint function in severe haemophilia. Secondary prophylaxis in children has also been shown to have a more beneficial effect on joint protection as on-demand treatment. The outcome of delayed secondary prophylaxis started in adulthood is rarely studied. The case of a man (age: 47 years) with severe haemophilia A demonstrates the successful switch from on-demand therapy to prophylaxis with subsequent reduction of annual bleeding rate and number of days of work lost. The small increase of factor VIII consumption (16%) and the decrease of bleeding rate are compared with data from two recently published prospective studies. Conclusion: An optimal dosing schedule needs to be discussed and larger and longer prospective studies targeting the benefits of secondary prophylaxis with factor VIII started in adulthood are necessary.
引用
收藏
页码:241 / 244
页数:4
相关论文
共 50 条
  • [41] Spectrum of factor VIII mutations in Arab patients with severe haemophilia A
    Abu-Amero, K. K.
    Hellani, A.
    Al-Mahed, M.
    Al-Sheikh, I.
    HAEMOPHILIA, 2008, 14 (03) : 484 - 488
  • [42] Modified Haemophilia Joint Health Scores (MHJHS) Outcomes with Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) Prophylaxis in Subjects with Severe Haemophilia A
    Oldenburg, J.
    Srivastava, A.
    Mahlangu, J.
    Blanchette, V.
    Kulkarni, R.
    Li, S.
    Tsao, E.
    Jain, N.
    HAEMOPHILIA, 2016, 22 : 68 - 69
  • [43] A Comparison of the Incidence Rate for Joint Bleeding and FVIII Consumption between On-Demand versus Prophylaxis Factor VIII Replacement Therapy and the Direct Cost of Prophylaxis Treatment in Severe Haemophilia A Patients
    Jamal, Munirah
    Sathar, Jameela
    Jamari, Jamaliah
    Saffian, Shamin Mohd
    MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2023, 30 (01): : 129 - 136
  • [44] Factor VIII prophylaxis for adult patients with severe hemophilia A: results of a US survey of attitudes and practices
    Walsh, C. E.
    Valentino, L. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 824 - 824
  • [45] Low-Dose Emicizumab Versus Low-/Intermediate-Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype
    Kessakorn, Nuchanun
    Gosriwatana, Itsaraet
    Sasipong, Nuttarak
    Srichumpuang, Chonlatis
    Moonla, Chatphatai
    Sosothikul, Darintr
    HAEMOPHILIA, 2025, 31 (01) : 122 - 131
  • [46] Another variant pattern of intron 22 inversion in the factor VIII gene seen in a severe haemophilia A patient
    Enayat, MS
    Theophilus, BDM
    Williams, MD
    Wilde, JT
    Hill, FGH
    THROMBOSIS AND HAEMOSTASIS, 1997, 78 (04) : 1303 - 1303
  • [47] Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A
    Mullins, E. S.
    Stasyshyn, O.
    Alvarez-Roman, M. T.
    Osman, D.
    Liesner, R.
    Engl, W.
    Sharkhawy, M.
    Abbuehl, B. E.
    HAEMOPHILIA, 2017, 23 (02) : 238 - 246
  • [48] Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT® in patients with severe haemophilia A without inhibitors
    Alvarez-Roman, M. T.
    Fernandez-Bello, I.
    de la Corte-Rodriguez, H.
    Hernandez-Moreno, A. L.
    Martin-Salces, M.
    Butta-Coll, N.
    Rivas-Pollmar, M. I.
    Rivas-Munoz, S.
    Jimenez-Yuste, V.
    HAEMOPHILIA, 2017, 23 (01) : E50 - E54
  • [49] Improvement of the quality of health care for children with severe haemophilia a using prophylaxis and treatment of bleeding episodes with recombinant factor VIII
    Glamocanin, S.
    Trajkova-Antevska, Z.
    Coneska, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 856 - 856
  • [50] Emicizumab prophylaxis for the treatment of infants with severe haemophilia A without factor VIII inhibitors: primary analysis of the HAVEN 7 study
    Pipe, S. W.
    Collins, P.
    Dhalluin, C.
    Kenet, G.
    Schmitt, C.
    Buri, M.
    Jimenez-Yuste, V.
    Peyvandi, F.
    Young, G.
    Oldenburg, J.
    Mancuso, M. E.
    Kavakli, K.
    Kiialainen, A.
    Niggli, M.
    Chang, T.
    Lehle, M.
    Fijnvandraat, K.
    HAEMOPHILIA, 2024, 30 : 24 - 25